Remdesivir in COVID-19
Remdesivir is a broad-spectrum antiviral drug that has previously demonstrated in vitro and in vivo activity against the viral pathogens MERS and SARS, which are also coronaviruses having structural similarity to COVID-19. Recent clinical studies have shed light on the potential benefits of Remdesivir in Covid-19 patients. The drug has been approved in Japan and the UK for the treatment of coronavirus, and the FDA has granted it emergency use authorization. The EMA has recommended the compassionate use of the drug.
The purpose of this whitepaper is to highlight the current regulatory scenario and clinical developments for Remdesivir for COVID-19. The whitepaper gives an account of the approval status and the critical clinical trials of Remdesivir for coronavirus treatment. It also brings into view the scenario of the drug's availability in low-income and lower-middle-income countries.
Through this whitepaper, DelveInsight gives its readers a look into the global regulatory and clinical development scenario of Remdesivir for COVID-19 and how, despite limited clinical studies, is currently the most suitable treatment option for coronavirus.